Today: 21 March 2026
Subscribe
Browse Category

NASDAQ:ATRA 12 January 2026 - 9 March 2026

Atara Biotherapeutics Stock Jumps 18% as FDA Shake-Up Puts Ebvallo Back in Focus

Atara Biotherapeutics Stock Jumps 18% as FDA Shake-Up Puts Ebvallo Back in Focus

Atara Biotherapeutics shares jumped 18% Monday after reports that FDA biologics chief Vinay Prasad will depart in April. The move follows the agency’s January rejection of Atara’s EBVALLO therapy for a rare blood cancer, which wiped out 56% of the stock’s value. Atara and partner Pierre Fabre have requested a Type A meeting with the FDA to revisit the decision. Atara ended 2025 with $8.5 million in cash.
9 March 2026
····
Atara Biotherapeutics stock dives on FDA EBVALLO rejection — what ATRA investors watch next

Atara Biotherapeutics stock dives on FDA EBVALLO rejection — what ATRA investors watch next

Atara Biotherapeutics shares fell 56% after the FDA rejected its cell therapy EBVALLO for a rare post-transplant cancer, citing insufficient evidence from the single-arm ALLELE study. The agency said previous manufacturing issues were resolved but requested new efficacy data. Atara and partner Pierre Fabre plan expedited talks with the FDA. The company reported $8.5 million in cash at year-end.
12 January 2026
··

Stock Market Today

  • Diageo Considers Guinness Spin Off Amid Portfolio Shift and Pricing Changes
    March 21, 2026, 12:33 PM EDT. Diageo (LSE:DGE) is reportedly exploring a spin off of its Guinness brand following weak financial results and shifting consumer demand towards lower-priced spirits. The move reflects a strategic reassessment of how Guinness fits within Diageo's portfolio, which includes Scotch, tequila, and vodka. Concurrently, the company is pursuing new brand partnerships and limited product launches, such as the IDL partnership for CÎROC Ultra Premium Vodka and a limited Oban 15 Year Old Port Cask Finish, aiming to maintain premium appeal despite consumer trends favoring value options. A Guinness spin off would reshape Diageo's capital allocation and portfolio balance, potentially leaving a more spirits-heavy mix to justify marketing investments. Investors should watch how these changes impact the balance between premium and value offerings, as well as future cash flow resilience.
Go toTop